Leap Therapeutics’ (LPTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Leap Therapeutics (NASDAQ:LPTX) in a research note issued to investors on Thursday,Benzinga reports. HC Wainwright currently has a $5.50 price objective on the stock.

Leap Therapeutics Price Performance

Shares of NASDAQ LPTX opened at $2.55 on Thursday. The stock has a market capitalization of $97.72 million, a price-to-earnings ratio of -1.32 and a beta of 0.17. The business has a 50-day moving average of $2.98 and a 200-day moving average of $2.76. Leap Therapeutics has a fifty-two week low of $1.68 and a fifty-two week high of $4.79.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Key Client Fiduciary Advisors LLC increased its stake in shares of Leap Therapeutics by 12.2% during the 4th quarter. Key Client Fiduciary Advisors LLC now owns 361,253 shares of the company’s stock worth $1,039,000 after purchasing an additional 39,330 shares during the last quarter. HB Wealth Management LLC grew its holdings in Leap Therapeutics by 103.2% during the fourth quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock worth $150,000 after purchasing an additional 26,150 shares during the period. Exome Asset Management LLC bought a new position in Leap Therapeutics during the third quarter worth about $264,000. Geode Capital Management LLC lifted its position in shares of Leap Therapeutics by 18.0% in the third quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock valued at $847,000 after buying an additional 50,194 shares during the last quarter. Finally, HighTower Advisors LLC bought a new position in shares of Leap Therapeutics during the 3rd quarter worth approximately $65,000. Institutional investors and hedge funds own 30.46% of the company’s stock.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.